The European Society for Paediatric Infectious Diseases is offering free access to 5 top sessions from ESPID 2019. 5 sessions, 20 webcasts will be publicly accessible until July 31: https://espidmeeting.org/live-streamed-sessions

 

Biographical sketches can be viewed here.  Click here for the Ballot.

Innovative Tool Offers Expert Guidance to Help Prevent Infections in Children

A new comprehensive resource provides practical, expert guidance for the urgent fight against healthcare-associated infections in children across a wide range of medical settings. Available to pre-order now, the Handbook of Pediatric Infection Prevention and Control fills an important gap in the healthcare field by addressing the nuances and challenges specific to preventing infections in children, from the clinic to the intensive care unit and beyond.

“Children are not just tiny adults, and this impacts many aspects of their medical care, including infection prevention,” said handbook co-editor Kristina A. Bryant, MD, professor of pediatrics in the Division of Pediatric Infectious Diseases at the University of Louisville and the healthcare epidemiologist at Norton Children’s Hospital. “This book offers practical guidance and solutions for the unique infection prevention challenges that providers encounter in pediatric settings on a daily basis.”

Developed by the Pediatric Infectious Diseases Society, the world’s largest organization focused on the treatment, control, and eradication of infectious diseases that affect children, the handbook addresses various infections and related issues across the spectrum of healthcare settings, from acute care hospitals and ambulatory practices to long-term care facilities. Covered topics include respiratory pathogens, surgical site infections, multidrug-resistant organisms, C. difficile, norovirus, device-associated infections, and antimicrobial stewardship, among many others.

Order your copy of the 
Handbook of Pediatric Infection Prevention and Control here!
Enter Promo Code AMPROMD9 to save 30%

*View the Handbook of PEDIATRIC INFECTION PREVENTION and CONTROL Flyer here.

 

 
 
 

Deadline Next Week
IDWeek Call for Abstract and Cases

Time is running out to submit an abstract or case for presentation at IDWeek 2019 in Washington, DC, Oct. 2-6. Travel awards and grants up to $2500 are available, so be sure to finish your submission by next Wednesday, May 1 at 5 p.m. EDT. No extensions will be given.

Share your original research and outstanding case with more than just the 8,000 ID professionals that will be attending IDWeek 2019. Abstracts will be published in the fully open access online journal Open Forum Infectious Diseases. View the science presented at last year’s IDWeek. Accepted cases will be published online at www.idimages.org. Create a free login and view the cases that were accepted at previous IDWeek conferences.

Important Dates

Abstract + Case + Travel Award Deadline
May 1, 5 p.m. EDT
 
IDEA Incubator Deadline
May 8, 5 p.m. EDT
 
Discounted Early Registration Deadline
June 28

IDWeek 2019, Washington, D.C.
Oct. 2-6

     

 

 

 

A joint meeting of:

 

Copyright © 2019 IDWeek. All Rights Reserved.
This message is an advertisement.

IDWeek | Phone: (703) 740-4961

www.idweek.org

Privacy Policy

Unsubscribe

Dear Colleague,

I am excited to announce an exciting opportunity for trainees in the field of transplant infectious diseases. This year, we are inviting trainees to attend our 3rd Symposium on Infectious Diseases in the Immunocompromised Host on June 10-11 in Seattle, WA. We are proud to feature a stellar line-up of speakers. The full list of scheduled talks can be found on our website at: www.fredhutch.org/infectious-disease-symposium

One key objective of our Training Program is to create opportunities for trainees and expand their interest and training horizons in infectious diseases. We feel it important to bring in as many trainees as possible to give them access to mentors and exposure to current topics in the field. We also feel that it’s important to extend this opportunity to as many institutions and communities as possible, and that you can help us spread the word. Please forward this announcement to trainees at all stages of their training/education, including medical students, residents, and fellows who are interested in infectious diseases in immunocompromised patients. Under-represented minority* trainees are strongly encouraged to apply. See the Travel Stipend page of our website for eligibility information and application.

I appreciate your help distributing this announcement. Finally, if you are interested in attending the symposium yourself, we’d be delighted to have the honor of your presence at our event. Continuing education credits for physicians, nurses, and pharmacists are available. 

Please let me know if you have any questions, or you can also contact Angela Mittmann (copied on this email) at This email address is being protected from spambots. You need JavaScript enabled to view it. or 206-667-6765 for assistance.

We encourage you to follow us on Twitter and Instagram at @HutchIDScience for all the latest updates, and connect to the conversation using the hashtag #IDSymp19.

Regards,

Michael Boeckh, MD
Head, Infectious Disease Sciences Program
Member, Vaccine and Infectious Disease Division
Fred Hutchinson Cancer Research Center
Professor, Department of Medicine
University of Washington
Seattle, WA, USA 

 

Confirmed speakers, moderators and chairs include:

Lilian Abbo

University of Miami

Angela Campbell

Center for Disease Control

Roy Chemaly

The University of Texas MD Anderson Cancer

Sanjeet Dadwal

City of Hope

Ferric Fang

University of Washington, Harborview Medical Center

Brian Fisher

Children's Hospital of Philadelphia

Cynthia Fisher

University of Washington

David Fredricks

Fred Hutchinson Cancer Research Center, University of Washington

Rebecca Gardner

Seattle Children’s Hospital

Joshua Hill

Fred Hutchinson Cancer Research Center, University of Washington

Tobias Hohl

Memorial Sloan Kettering

Michael Ison

Northwestern University

YaeJean Kim

Samsung Medical Center, Seoul, South Korea

Dimitrios Kontoyiannis

The University of Texas MD Anderson Cancer

Camille Kotton

Massachusetts General Hospital

Ajit Limaye

University of Washington, Fred Hutchinson Cancer Research Center

Catherine Liu

Fred Hutchinson Cancer Research Center, University of Washington

Per Ljungman

Karolinska University Hospital, Karolinska Institutet, Sweden

Kieren Marr

Johns Hopkins University School of Medicine

Francisco Marty

Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School

Genovefa Papanicolaou

Memorial Sloan Kettering Cancer Center

John Perfect

Duke University

Steve Pergam

Fred Hutchinson Cancer Research Center, University of Washington

Christopher Polage,

Duke University   

Issam Raad

The University of Texas MD Anderson Cancer Center

Krishna Rao

University of Michigan

Susan Seo

Memorial Sloan Kettering Cancer Center

Nina Singh

University of Pittsburgh

Monica Slavin

University of Melbourne, National Centre for Infections in Cancer, Australia

Casey Theriot

North Carolina State University             

Sara Vora

Seattle Children’s Hospital

Alpana Waghmare

Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center

Scott Weissman

Seattle Children’s Hospital

Joshua Wolf

St. Jude’s Children’s Hospital

Christopher Woods

Duke University

* Per NIH training grant guidelines, individuals with disabilities and those from the following racial and ethnic groups have been shown to be underrepresented in the health sciences: American Indians or Alaska Natives, Blacks or African Americans, Hispanics or Latinos, and Native Hawaiians or Other Pacific Islanders.

INFECTIOUS DISEASE SCIENCES

FRED HUTCHINSON CANCER RESEARCH CENTER

Join the conversation on Twitter @HutchIDScience 

 

Press Release

For Immediate Release
Tuesday, September 25, 2018

Contact: Media Relations
(404) 639-3286

The United States announced today, during the United Nations (UN) General Assembly in New York, The AMR Challenge—the most ambitious global initiative to date to combat the growing threat of antibiotic resistance (AR or AMR). This unprecedented challenge, led by the U.S Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC), charges pharmaceutical and health insurance companies, food animal producers and purchasers, medical professionals, government health officials, and other leaders from around the world to work together to address antibiotic resistance by:

  • reducing antibiotics and resistance in the environment (e.g. in water and soil);
  • improving antibiotic use, including ensuring people can access these medicines when they are needed;
  • developing new vaccines, drugs, and diagnostic tests;
  • improving infection prevention and control; and
  • enhancing data sharing and data collection.

HHS Secretary Alex Azar will announce the challenge tonight at a U.S. event co-hosted by the Bill & Melinda Gates Foundation, the Pew Charitable Trusts, the United Nations Foundation, Wellcome Trust, and the CDC Foundation. Secretary Azar will unveil the first commitments from more than 100 organizations intent on building on progress against one of the greatest global public health threats. 

PEDIATRIC ID FELLOWS – WE WANT TO HEAR FROM YOU!

The PIDS Career Paths Working Group is pleased to announce a call for videos for the 2017 PIDS Fellow Video Competition. The goal of this competition is to gather videos that show the varied and exciting opportunities within the field of pediatric ID. The rules are simple: Compose a short video about why you chose pediatric ID. Top videos will be posted on the PIDS YouTube channel, promoted through social media and announced in PIDSNews. Winners (up to three fellows per video selected) will receive paid registration to attend the 2017 IDWeek meeting.

Video Format

Videos should be a maximum of 3 minutes long and may combine screen shots, interviews, music, or other content. We highly encourage creativity and a sense of humor but videos should also contain serious content and should be professional in tone. We welcome videos that:

  • Show a typical day in the life of a pediatric ID fellow
  • Highlight varied career opportunities within the field of ID
  • Attract potential applicants to the field of pediatric ID
  • Recount rewarding patient experiences or influential mentors

Please note that this list is not exhaustive. Please also note that videos should contain only material for which the authors own copyright. Clips from films or television, and music for soundtrack, should only be used if copyright permission has been granted by the copyright holders, and this written permission accompanies the video submission.

Videos must be submitted in a widely supported encoding and container format. 

Submission Instructions

Submit your video by submitting it to the PIDS DropBox account, by clicking here. All submissions are due no later than June 30, 2017.

Review and Award Process

Submitted videos will be reviewed by members of the PIDS Communications Committee. Top videos will be posted on the PIDS YouTube channel, promoted through social media and announced in PIDSNews.

Review Criteria:

  1. Content and relevance 
  2. Entertainment value
  3. Presentation

Key Dates

Submission Deadline: June 30, 2017
Award Notifications: August 31, 2017

For further information please contact: 
Christy Phillips, PIDS Headquarters
703-299-9865, This email address is being protected from spambots. You need JavaScript enabled to view it. 

We look forward to your participation in this exciting competition!

PIDS Communications Committee and the PIDS Career Paths Working Group

 

The ABP recently issued the spring edition of the Program Director's Newsletter. This issue will update you on the ABP's New Program Portal, a new Subspecialty Fellow Orientation Slide Deck, as well as the NEW Fellowship Start Date recommended by the Council on Pediatric Subspecialties. For more information and to read the newsletter in its entirety, please click here.

PIDS is concerned that there has not been an update on the promised price reduction for Daraprim (pyrimethamine) and further that the $750 price per tablet is impacting patient access to this essential treatment. We are working with IDSA, HIVMA and the National Alliance of State and Territorial AIDS Directors (NASTAD) to monitor and document challenges accessing the medication.

We want to know if you are aware of any access issues to Daraprim (pyrimethamine) since the price increase by Turing Pharmaceuticals. Please let us know if you, your colleagues or your hospital or clinic has experienced any of the issues below.

  • Had problems accessing therapy during inpatient admissions
  • Had to use alternative therapies for treatment of toxoplasmosis or malaria
  • Had to prolong hospitalizations until patients could access drug as an outpatient
  • Had to switch therapy or had lapses in dosing for ongoing treatment or prophylaxis
  • Had difficulties accessing Daraprim (pyrimethamine) through the patient assistance program
  • Used the patient assistance program (please let us know how it works)
  • Had patients unable to obtain Daraprim (pyrimethamine) through the state AIDS Drug Assistance Program
  • Had patients unable to obtain Daraprim (pyrimethamine) through their regular pharmacy

Please share your comments with us online or by contacting us via This email address is being protected from spambots. You need JavaScript enabled to view it.. Please note if you post comments online they will be available for public viewing.

The Antibacterial Resistance Leadership Group (ARLG) (www.arlg.org) is tasked by the National Institute of Allergy and Infectious Diseases (NIAID) with prioritizing, designing, implementing and conducting clinical research to address the growing public health threat of antibacterial resistance.

The ARLG has identified four high-priority areas of research: infections caused by Gram-negative bacteria, infections caused by Gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses one or more of these high-priority areas.

The ARLG Structure includes seven committees: The Executive Committee (EC) is ultimately responsible for all ARLG activities, including high-level scientific and management decisions, finalizing the research agenda, and approving and funding studies for protocol development and implementation. The EC is charged with ensuring optimal stewardship of precious ARLG resources, including reallocation as needed. It also oversees and coordinates three centers: the Leadership and Operations Center (LOC), the Laboratory Center (LC), and the Statistics and Data Management Center (SDMC).

The Steering Committee (SC) facilitates communication between the ARLG leadership, Scientific Subcommittees, and Special Emphasis Panels (SEPs). It reports to and advises the ARLG EC. The SC has primary responsibility for setting scientific priorities and the research agenda. This includes proposing protocols that advance the ARLG scientific agenda, reviewing research proposals, identifying new developments in the field, assessing medical needs, providing scientific oversight of protocols during design and execution, and, prioritizing and re-prioritizing studies as needed.

ARLG Fig

There are four Scientific Subcommittees, each corresponding to one of the four prioritized research areas: 1) the Gram-Negative Subcommittee, 2) the Gram-Positive Subcommittee, 3) the Antimicrobial Stewardship and Infection Prevention Subcommittee, and 4) the Diagnostics and Devices Subcommittee. There are three SEPs: 1) Special Populations, 2) Pharmacokinetics, and 3) Pediatrics. The purpose of these SEPs is to serve as a cross cutting resource for the Scientific Subcommittees and the Executive Committee. The Scientific Subcommittees and SEPs provide topic-specific expertise and are responsible for reviewing and evaluating research proposals to ensure high quality protocols that advance the ARLG scientific agenda are selected.

Research proposals can originate from any source including the general scientific community, sites, industry, or from within ARLG infrastructure. Regardless of origin, all research proposals undergo a standardized process of evaluation for scientific merit, impact and feasibility. Proposals are reviewed and evaluated on the basis of four key questions: 1) Is the proposed research responsive to the scope or mission of the ARLG? 2) Is it scientifically important? 3) Can it be completed on time and within budget? 4) Is this a unique opportunity to conduct research that could not be accomplished by other means?

Standardized forms have been developed to facilitate the submission and review process. The application consists of an on-line (www.arlg.org), one-page concept sheet describing the key elements of the proposal and a four-page form for supplemental documentation. Research proposals are reviewed by one or more Scientific Subcommittees and Special Emphasis Panels, as appropriate. For example, a study involving Gram-negative infections in children would be assigned to the Gram-negative Subcommittee for primary review and the Pediatric Special Emphasis Panel for secondary review. Proposals will be evaluated for significance, innovation, approach, and overall impact and ranked according to the overall impact score. Reviewers' comments and scores will be reported to and reviewed by the SC which will make recommendations to the EC as to which projects should undergo further review for feasibility and possible implementation.

Application types. Applications are of three general types:

  1. Research Proposals - Proposals for clinical studies (e.g., randomized controlled trials that may become part of regulatory submissions, case-control studies, cohort studies) to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens will be considered responsive to the scientific mission of ARLG. Applications that propose pre-clinical or non-clinical research, studies of non-bacterial infections, or research not directly related to antibiotic resistance will be considered non-responsive. Apply at www.arlg.org.
     
  2. Early Stage Investigator (ESI) Seed Grants - ESIs (defined as MD, PhD, or PharmD students, graduate or post-graduate trainees, or individuals with a faculty appointment for < 5 years) may apply for seed grants of up to $50,000 direct costs. Seed grants provide a mechanism by which ESIs can obtain funds for an AR-related research project. Apply at www.arlg.org.
     
  3. ARLG Fellowship Training Program - The ARLG Fellowship is a two-year, fully funded, competitive opportunity to acquire expertise in AR-relevant clinical research. Participants gain both hands-on and formal didactic training by immersion in ARLG projects and operations and class work leading to a Masters of Health Sciences in Clinical Research or equivalent degree. Initially, this fellowship will be at Duke due to the central location with ARLG operations at the Duke Clinical Research Institute (DCRI), but later fellowships could be at other institutions, provided that appropriate infrastructure and involvement in day-to-day ARLG clinical trial operations are available. Fellowship applications are due at the end of October each year to begin the following July. Apply at www.arlg.org

The hope is that PIDS membership will create applications suitable for consideration. There is a real opportunity to do clinical studies, unique to children and gain funding for them with dollars that originate at NIAID.

Questions are welcome. Please contact me or any member of the Pediatric SEP by Email or by any other means. We would love to help.

Thanks Robert Daum MD. This email address is being protected from spambots. You need JavaScript enabled to view it. on behalf of the Pediatric Special Emphasis Panel. (Buddy Creech, Charlie Huskins, Theo Zaoutis and Danny Benjamin).

The Pediatric Infectious Diseases Society, Editor-in-Chief Theoklis E. Zaoutis, MD, MSCE, and Oxford University Press invite you to submit your next article to JPIDS.

JPIDS is soliciting submissions of drawings that will illustrate the covers of our journal, JPIDS. We are looking for submissions that demonstrate unique artistic vision and creativity with a theme that relates to pediatric infectious disease. For more information, please visit: Cover Art Contest.

Attention Fellowship Training Program Directors

The Infectious Diseases Society of America (IDSA) and the National Institute of Allergy and Infectious Diseases (NIAID) are pleased to announce an exciting new program designed to help foster the next generation of infectious diseases physician scientists.  The inaugural two-day meeting for ID fellows and medical students will take place on the campus of the National Institutes of Health in Bethesda, MD from May 17-19, 2012.  Travel costs will be provided for meeting participants.

(For PIDS Clinically Active Members Who Require Board Certification)

This is an EASY step-by-step quick instruction set for figuring out what you need to do to keep your pediatric infectious diseases certification current. For more information, please click here.